Back to Awarded Treatment Trials
Awarded Trial: 06T-773
Grant ID
06T-773
Illness
Schizophrenia
Primary Drug/Intervention
Curcumin C3 complex
Primary Dosage
1 or 4 g/day
Secondary Drug Intervention
N/A
Secondary Dosage
N/A
Other Drug/Intervention
N/A
Other Dosage
N/A
Status
Completed
Investigator
Chiu
Sample Size
16
Duration of Study Period for Each Subject
16 weeks
Outcome Measurements
BPRS, PANSS, cognitive battery, serum markers of inflammation
Results
Circumin has anti-inflammatory and HDAC inhibitory properties and comes from the curry plant. Thus it is thought to affect epigentic mechanisms. In this preliminary open-label study, 17 patients with schizophrenia were given curcumin 4 mg (n=8) or 1 mg (n=7) per day for 16 weeks. Clinical symptoms improved over the 16 weeks as assessed by total PANSS and general psychopathology (p<0.003 and <0.002 for 1 gm. and <0.01 and 0.016 for 4 gms).
Publication
Submitted.
Link
N/A
PI Name
Simon Chiu
Degree
MD
Center
MSA Ltd.
Institution
University of Western Ontario Research Park
Address
100 Collip Circle, Suite 230 A
City or Town
London
State or Province
Ontario
Zip or Postal Code
N6G 4X8
Country
Canada
Email Address
schiu3207@rogers.com